|
1
|
Liebner DA and Shah MH: Thyroid cancer:
Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab.
2:173–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lloyd RV, Buehler D and Khanafshar E:
Papillary thyroid carcinoma variants. Head Neck Pathol. 5:51–56.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Das S, Chaudhary N, Ang LC and Megyesi JS:
Papillary thyroid carcinoma metastasizing to anaplastic meningioma:
An unusual case of tumor-to-tumor metastasis. Brain Tumor Pathol.
34:130–134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nikiforov YE and Nikiforova MN: Molecular
genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol.
7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu S, Semenciw R, Ugnat AM and Mao Y:
Increasing thyroid cancer incidence in Canada, 1970–1996: Time
trends and age-period-cohort effects. Br J Cancer. 85:1335–1339.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pemayun TG: Current diagnosis and
management of thyroid nodules. Acta Med Indones. 48:247–257.
2016.PubMed/NCBI
|
|
7
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia L, Zhang D, Qi X, Ma B, Xiang Z and He
N: Identification of the conserved and novel miRNAs in Mulberry by
high-throughput sequencing. PLoS One. 9:e1044092014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie B, Ding Q, Han H and Wu D: miRCancer:
A microRNA-cancer association database constructed by text mining
on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mutalib NS, Yusof AM, Mokhtar NM, Harun R,
Muhammad R and Jamal R: MicroRNAs and lymph node metastasis in
papillary thyroid cancers. Asian Pac J Cancer Prev. 17:25–35. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu J, Li J, Zheng TH, Bai L and Liu ZJ:
MicroRNAs in the occurrence and development of primary
hepatocellular carcinoma. Adv Clin Exp Med. 25:971–975. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hamam R, Hamam D, Alsaleh KA, Kassem M,
Zaher W, Alfayez M, Aldahmash A and Alajez NM: Circulating
microRNAs in breast cancer: Novel diagnostic and prognostic
biomarkers. Cell Death Dis. 8:e30452017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Irmak-Yazicioglu MB: Mechanisms of
MicroRNA deregulation and MicroRNA targets in gastric cancer. Oncol
Res Treat. 39:136–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang M, Wu W, Gao M and Fei Z:
MicroRNA-451 as a prognostic marker for diagnosis and lymph node
metastasis of papillary thyroid carcinoma. Cancer Biomark.
19:437–445. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Li Q, Li R, Ren P and Dong S:
MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by
targeting PIK3CA. Am J Cancer Res. 7:148–158. 2017.PubMed/NCBI
|
|
16
|
Zhao H, Tang H, Huang Q, Qiu B, Liu X, Fan
D, Gong L, Guo H, Chen C, Lei S, et al: MiR-101 targets USP22 to
inhibit the tumorigenesis of papillary thyroid carcinoma. Am J
Cancer Res. 6:2575–2586. 2016.PubMed/NCBI
|
|
17
|
Gong H, Fang L, Li Y, Du J, Zhou B, Wang
X, Zhou H, Gao L, Wang K and Zhang J: miR873 inhibits colorectal
cancer cell proliferation by targeting TRAF5 and TAB1. Oncol Rep.
39:1090–1098. 2018.PubMed/NCBI
|
|
18
|
Cui J, Yang Y, Li H, Leng Y, Qian K, Huang
Q, Zhang C, Lu Z, Chen J, Sun T, et al: MiR-873 regulates ERα
transcriptional activity and tamoxifen resistance via targeting
CDK3 in breast cancer cells. Oncogene. 34:40182015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao D, Yu T and Ou X: MiR-873-5P controls
gastric cancer progression by targeting hedgehog-GLI signaling.
Pharmazie. 71:603–606. 2016.PubMed/NCBI
|
|
20
|
Chen XY, Chen RP, Wu W and Huang ZM:
MicroRNA-873 inhibits proliferation and induces apoptosis by
targeting CXCL1 in gastric cancer. Int J Clin Exp Pathol.
9:10011–10019. 2016.
|
|
21
|
Liu ZY, Zhou GY, Kakudo K and Lam AK:
Update on 2017 Who classification of tumors of thyroid gland.
Zhonghua Bing Li Xue Za Zhi. 47:302–306. 2018.(In Chinese).
PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Liu G, Wu S, Jiang F, Xie J and
Wang Y: Zinc finger E-box-binding homeobox 1: Its clinical
significance and functional role in human thyroid cancer. Onco
Targets Ther. 9:1303–1310. 2016.PubMed/NCBI
|
|
24
|
Wang Z, Zhang H, He L, Dong W, Li J, Shan
Z and Teng W: Association between the expression of four
upregulated miRNAs and extrathyroidal invasion in papillary thyroid
carcinoma. Onco Targets Ther. 6:281–287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Graham ME, Hart RD, Douglas S, Makki FM,
Pinto D, Butler AL, Bullock M, Rigby MH, Trites JR, Taylor SM and
Singh R: Serum microRNA profiling to distinguish papillary thyroid
cancer from benign thyroid masses. J Otolaryngol Head Neck Surg.
44:332015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A,
Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG
and Sidhu SB: MicroRNA-222 and microRNA-146b are tissue and
circulating biomarkers of recurrent papillary thyroid cancer.
Cancer. 119:4358–4365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su
JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits
glioblastoma tumorigenesis and metastasis by suppressing the
expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu DD, Li XS, Meng XN, Yan J and Zong ZH:
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells
by targeting ABCB1. Tumour Biol. 37:10499–10506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao Y, Xue Q, Wang D, Du M, Zhang Y and
Gao S: miR-873 induces lung adenocarcinoma cell proliferation and
migration by targeting SRCIN1. Am J Transl Res. 7:2519–2526.
2015.PubMed/NCBI
|
|
30
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Y, Xu L, Li A and Han X: The roles
of ZEB1 in tumorigenic progression and epigenetic modifications.
Biomed Pharmacother. 110:400–408. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma Y, Zheng X, Zhou J, Zhang Y and Chen K:
ZEB1 promotes the progression and metastasis of cervical squamous
cell carcinoma via the promotion of epithelial-mesenchymal
transition. Int J Clin Exp Pathol. 8:11258–11267. 2015.PubMed/NCBI
|
|
33
|
Larsen JE, Nathan V, Osborne JK, Farrow
RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, et
al: ZEB1 drives epithelial-to-mesenchymal transition in lung
cancer. J Clin Invest. 126:3219–3235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou YM, Cao L, Li B, Zhang RX, Sui CJ,
Yin ZF and Yang JM: Clinicopathological significance of ZEB1
protein in patients with hepatocellular carcinoma. Ann Surg Oncol.
19:1700–1706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jia B, Liu H, Kong Q and Li B:
Overexpression of ZEB1 associated with metastasis and invasion in
patients with gastric carcinoma. Mol Cell Biochem. 366:223–229.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo E, Wang Z and Wang S: MiR-200c and
miR-141 inhibit ZEB1 synergistically and suppress glioma cell
growth and migration. Eur Rev Med Pharmacol Sci. 20:3385–3391.
2016.PubMed/NCBI
|
